

# Plasma Protease C1-inhibitor Market Growing at 9.6% CAGR To Reach US\$ 7.96 Billion From 2024 to 2032

*The growing cases of Hereditary Angioedema (HAE) is a prominent factor driving the plasma protease C1-inhibitor market.*

NEW YORK CITY, NY, UNITED STATES, October 21, 2024 /EINPresswire.com/ -- The plasma protease C1-inhibitor market forecast for 2032 is a specialized study of the industry with a specific concentration on the global market trend analysis.



Plasma protease C1-inhibitor impedes proteases prohibiting immoderate redness and is important for sustaining hemostatic balance”

*Polaris Market Research*

“The plasma protease C1-inhibitor market is projected to reach US\$ 7.96 billion by 2032, growing at a CAGR of 9.6% from 2024 to 2032. The market is driven by the increasing prevalence of hereditary angioedema (HAE) and the growing demand for plasma-derived products. The market is expected to be dominated by the United States, followed by Europe and Asia. The market is highly competitive, with several key players including Baxter, CSL, and Takeda. The market is expected to continue to grow over the next decade, driven by the increasing prevalence of HAE and the growing demand for plasma-derived products.”

Plasma protease C1-inhibitor is the protease inhibitor associated with the serpin superfamily. Its prominent role is obstruction of the complement system to prohibit unconstrained initiation but also a prominent controller of the contact system. Dissimilar to the majority of family representatives, C-1 inhibitors have a two-domain framework. The C terminal serpin realm is homogenous to other serpins which is the constituent of C-1 inhibitor that offers the inhibitory venture.

Plasma protease C1-inhibitor is the protease inhibitor associated with the serpin superfamily. Its prominent role is obstruction of the complement system to prohibit unconstrained initiation but also a prominent controller of the contact system. Dissimilar to the majority of family representatives, C-1 inhibitors have a two-domain framework. The C terminal serpin realm is homogenous to other serpins which is the constituent of C-1 inhibitor that offers the inhibitory venture.

For more information, please contact:

<https://www.polarismarketresearch.com/industry-analysis/plasma-protease-c1-inhibitor-market/request-for-sample>

Insufficiency of this protein is linked with hereditary angioedema or inflammation due to the discharge of fluid from blood vessels into affinity tissue. Insufficiency of C-1 inhibitor allows plasma kallikrein initiation which causes the production of vasoactive peptide bradykinin. Also, the C4 and C2 cleavage goes unrestrained, causing an auto initiation of the complement system. The elevated consciousness of HAE causes premature observation, and cure incorporation is

impacting the plasma protease C1-inhibitor market growth favorably.

Key players in the plasma protease C1-inhibitor market include:

- BioCryst Pharmaceuticals, Inc.
- CENTOGENE N.V.
- CSL
- Fresenius Kabi
- Ionis Pharmaceuticals, Inc.
- KalVista Pharmaceuticals
- Pharming
- Sanquin
- Shire plc
- Takeda Pharmaceutical Company Limited

are some of the leading players in the plasma protease C1-inhibitor market.

Spearheading market contenders are funding massively in research and development so as to augment their product line which will assist the market to grow even more. Market contenders are also experiencing an assortment of tactical ventures to augment their global footprint, which are crucial market advancements involving commodity instigations and legitimate alliances.

Key events in the plasma protease C1-inhibitor market include:

- In May 2024, BioCryst Pharmaceuticals, Inc. showcased contemporary actual proof at ISPOR 2024, portraying notable depletion in healthcare assets usage in the US patients with hereditary angioedema (HAE) ensuing commencement of ORLADEYO.
- In May 2023, KalVista Pharmaceuticals showcased data at the premiere C-1 inhibitor Deficiency & Angioedema workroom, underscoring perspectives on sebetralstat's interim prophylaxis discipline.

For more information on the plasma protease C1-inhibitor market, visit:

<https://www.polarismarketresearch.com/industry-analysis/plasma-protease-c1-inhibitor-market/request-for-discount-pricing>

Advancement in Diagnostic Technologies: Progression in diagnostic technologies and genetic testing have additionally eased the recognition of persons with HAE, conducting to the

**POLARIS** MARKET RESEARCH **Plasma Protease C1-inhibitor Market**

**US\$ 7.96 BN**  
Revenue Forecast in 2032

Plasma Protease C1-inhibitor Market

augmenting patient reservoir. Further, the obtainability of productive cures such as C1-INH assists in handling and prohibiting drastic inflammation attacks.

**Surging Clinical Trials:** The market growth can be attributed to continuing clinical trials and research endeavors targeted at widening treatment alternatives and traversing contemporary symptoms beyond hereditary angioedema (HAE). This, in turn, is having a favorable impact on plasma protease C1-inhibitor market sales.

**Growing Healthcare Expenses:** The growing healthcare disbursement is a notable driver of the market. As nations assign more resources to healthcare frameworks and services, there is a pronounced accessibility and availability of specific therapies such as C1-INH.

Regional Market Outlook

**North America:** North America accounted for the largest plasma protease C1-inhibitor market share. The region's robust growth is primarily due to the elevated existence of HAE. This existence generates a sizeable demand for productive therapies, thereby providing notable to the market's growth.

**Asia Pacific:** Asia Pacific is anticipated to witness significant growth from 2024 to 2032. This can be attributed to the growing existence of detrimental inflammatory disorders and an escalating demand for progressive therapeutic solutions.

Market Outlook by Drug Class

**By Drug Class Outlook:**

- C1-inhibitors
  - o C1-esterase Inhibitor
  - o Recombinant Inhibitor
  
- Kallikrein Inhibitor
- Selective Bradykinin B2 Receptor Antagonist

**By Dosage Form Outlook:**

- Lyphophlised
- Injectables

**By Distribution Channel Outlook:**

- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies

**By Region Outlook:**

- North America (US, Canada)
- Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia)

- Asia Pacific (Japan, China, India, Malaysia, Australia, Indonesia, South Korea)
- Latin America (Brazil, Mexico, Argentina)
- Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)

□□□□□□ □□□□ □□□□ □□□□ □□□□□□ □□□□□□□□:

<https://www.polarismarketresearch.com/industry-analysis/plasma-protease-c1-inhibitor-market/inquire-before-buying>

□□□□:

How much is the plasma protease C1-inhibitor market?  
The market size was valued at USD 3.51 billion in 2023.

What is the growth rate of the plasma protease C1-inhibitor market?

The global market is projected to grow at a CAGR of 9.6% during the forecast period, 2024-2032.

Which region held the largest market share?

North America had the largest share of the global market.

Which drug class led the market?

The C1-inhibitors category dominated the market in 2023.

□□□□□□ □□□'□ □□□□□□ □□□□□□□□ □1-□□□□□□□□□□ □□□□□□ □□□□□□ □□□□□□□□ □□□□ □□□□□□□□□□:

<https://www.polarismarketresearch.com/industry-analysis/plasma-protease-c1-inhibitor-market> □□□□□□ □□□ □□□□□□□□□□, □□□□□□□□□□ □□ □□□□□ □□□ 7.96 □□□□□□□□ □□ 2032 □□□□□ 9.6% □□□□□ | □□□ □□□□□□□□- □□□□□□□□□□ □□□□□□□□□□□□□□□□, □□□□□, □□□□□□□□□□□ □.□.□, □□□□

□□□□□□ □□□□ □□□□□□□□ □□□□□□□□:

Equine Healthcare Market:

<https://www.polarismarketresearch.com/industry-analysis/equine-healthcare-market>

Hypnotherapy Market:

<https://www.polarismarketresearch.com/industry-analysis/hypnotherapy-market>

Immunoassay Market:

<https://www.polarismarketresearch.com/industry-analysis/immunoassay-market>

Dental Bone Graft Substitutes Market:

<https://www.polarismarketresearch.com/industry-analysis/dental-bone-graft-substitutes-market>

Zollinger-Ellison Syndrome Treatment Market:

<https://www.polarismarketresearch.com/industry-analysis/zollinger-ellison-syndrome-treatment-market>

Polymers, Polymers, Polymers & Polymers, Polymers:

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR's clientele spread across different enterprises. We at Polaris are obliged to serve PMR's diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR's customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR's customers.

Likhil G

Polaris Market Research and Consulting

+ + 1 929-297-9727

[sales@polarismarketresearch.com](mailto:sales@polarismarketresearch.com)

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/753534325>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.